Global Digital Breast Tomosynthesis Market 2017-2021
About Digital Breast Tomosynthesis
DBT (also known as 3D mammography) is a widely popular imaging technique. It offers clear breast imaging through volumetric reconstruction of the breast from a countable number of low-dose two-dimensional projections obtained with the help of an X-ray tube. DBT offers superior benefits over the other existing imaging modalities, as it early detects cancer more precisely in the dense breast tissues.
Technavio’s analysts forecast the global digital breast tomosynthesis market to grow at a CAGR of 11.05% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global digital breast tomosynthesis market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Digital Breast Tomosynthesis Market 2017-2021
Technavio recognizes the following companies as the key players in the global digital breast tomosynthesis market: Hologic, GE Healthcare, Philips Healthcare, Siemens Healthcare, FUJIFILM, and IMS - Internazionale Medico Scientifica.
Other Prominent Vendors in the market are: Agfa-Gevaert, Carestream Health, MEDI-FUTURE, Metaltronica, PerkinElmer, Planmed, Shimadzu, Toshiba Medical Systems, and Trivitron Healthcare.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is new product launches/approvals coupled with R&D activities. Vendors are increasingly focusing on the development and launch of advanced DBT equipment. New product launches combined with R&D activities enable the vendors to sustain in the market and to enhance their growth. Vendors are actively involved in launching innovative devices for improving comfortability and accuracy of the mammographic images.”
According to the report, one driver in the market is global rise in breast cancer cases. Breast cancer is considered as an inevitable disease and is one of the main causes of high mortality in women. The demand for DBT increased significantly in recent years owing to the accuracy and superiority over the 2D mammography. There is a countable rise in the number of incidence rate from past 25 years, particularly among postmenopausal women. For instance, in 2013, the CDC estimated that 100,000 women encountered breast cancer each year during 1999-2013. In 2012, 1.7 million people were diagnosed with breast cancer, and it accounts for 12% of the global cancer ratio and resulting in the death of 6% (522,000) individuals.
Further, the report states that one challenge in the market is high cost of mammography equipment. Medical imaging procedures such as DBT are the most revenue generating areas for any healthcare facility. However, DBT equipment is expensive and classified as capital equipment that requires budget allocation and high maintenance. Although there is a rising shift toward the DBT over the conventional mammography among the end-users, the high cost of equipment will have an adverse impact on the market growth. The cost of a DBT system is 3-5 times more than that of an analog mammography system or conventional analog mammography system.
Hologic, GE Healthcare, Philips Healthcare, Siemens Healthcare, FUJIFILM, and IMS - Internazionale Medico Scientifica, Agfa-Gevaert, Carestream Health, MEDI-FUTURE, Metaltronica, PerkinElmer, Planmed, Shimadzu, Toshiba Medical Systems, and Trivitron Healthcare.